International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(16), P. 9026 - 9026
Published: Aug. 20, 2024
Colorectal
cancer
(CRC)
continues
to
be
a
significant
contributor
global
morbidity
and
mortality.
Emerging
evidence
indicates
that
disturbances
in
gut
microbial
composition,
the
formation
of
reactive
oxygen
species
(ROS),
resulting
inflammation
can
lead
DNA
damage,
driving
pathogenesis
progression
CRC.
Notably,
bacterial
metabolites
either
protect
against
or
contribute
oxidative
stress
by
modulating
activity
antioxidant
enzymes
influencing
signaling
pathways
govern
ROS-induced
inflammation.
Additionally,
microbiota
byproducts,
when
supplemented
through
probiotics,
affect
tumor
microenvironments
enhance
treatment
efficacy
selectively
mediate
destruction
CRC
cells.
This
review
aims
discuss
mechanisms
which
taxonomical
shifts
related
such
as
short-chain
fatty
acids,
secondary
bile
trimethylamine-N-oxide
influence
ROS
concentrations
safeguard
promote
onset
inflammation-mediated
we
focus
on
role
probiotic
ROS-mediated
both
status
inflammation,
Nrf2-Keap1,
NF-κB,
NLRP3
mitigate
carcinogenesis.
Overall,
deeper
understanding
may
aid
delaying
preventing
offer
new
avenues
for
adjunct,
CRC-specific
therapeutic
interventions
immunotherapy.
Gut Microbes,
Journal Year:
2025,
Volume and Issue:
17(1)
Published: April 20, 2025
The
pathogenesis
of
cancer
is
closely
related
to
the
disruption
homeostasis
in
human
body.
gut
microbiome
plays
crucial
roles
maintaining
its
host
throughout
lifespan.
In
recent
years,
a
large
number
studies
have
shown
that
dysbiosis
involved
entire
process
initiation,
development,
and
prognosis
by
influencing
immune
system
metabolism.
Some
specific
intestinal
bacteria
promote
occurrence
development
cancers
under
certain
conditions.
Conversely,
some
other
suppress
oncogenesis
progression
cancers,
including
inhibiting
delaying
boosting
therapeutic
effect
on
cancers.
promoting
effects
been
comprehensively
discussed
previous
review.
This
article
will
review
latest
advances
mechanisms
suppression,
providing
new
perspective
for
developing
strategies
prevention
treatment.
Thoracic Cancer,
Journal Year:
2025,
Volume and Issue:
16(9)
Published: May 1, 2025
ABSTRACT
Background
The
gut
microbiome
influences
the
host
immune
system,
cancer
development
and
progression,
as
well
response
to
immunotherapy
during
treatment.
Here,
we
analyse
composition
of
bacteriome
in
metastatic
Non‐Small
Cell
Lung
Cancer
(NSCLC)
patients
receiving
Pembrolizumab
within
a
prospective
maintenance
trial
through
opportunistic
sampling
Methods
profiles
NSCLC
were
obtained
from
stool
samples
collected
treatment
analysed
with
16S
rRNA
metagenomics
sequencing.
Patient
compared
group
healthy
individuals
matching
ethnic
group,
age,
sex,
BMI
comorbidities.
Results
A
significant
decrease
treated
was
observed
two
prominent
bacterial
families
phylum
Firmicutes,
Lachnospiraceae
Ruminoccocaceae,
which
comprised
31.6%
21.8%
but
only
10.9%
14.2%
patient
respectively.
Species
Ruminococcaceae
are
known
break
down
undigested
carbohydrates
generating
short
chain
fatty
acids
(SCFA),
such
butyrate,
acetate
propionate
their
major
fermentation
end‐products,
have
been
implicated
modifying
responses.
In
addition,
increase
Bacteroidacaeae
family
(Bacteroidetes
phylum)
10.7%
23.3%
group.
Moreover,
agreement
previous
studies,
Firmicutes
Bacteroidetes
ratio
Pembrolizumab‐treated
observed.
Conclusion
differences
indicate
dysbiosis
compromised
intestinal
health
status
patients.
This
data
could
inform
future
studies
responses
modulation
minimise
prior
or
concurrent
Trial
Registration:
SWIPE
(NCT
02705820).
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(16), P. 9026 - 9026
Published: Aug. 20, 2024
Colorectal
cancer
(CRC)
continues
to
be
a
significant
contributor
global
morbidity
and
mortality.
Emerging
evidence
indicates
that
disturbances
in
gut
microbial
composition,
the
formation
of
reactive
oxygen
species
(ROS),
resulting
inflammation
can
lead
DNA
damage,
driving
pathogenesis
progression
CRC.
Notably,
bacterial
metabolites
either
protect
against
or
contribute
oxidative
stress
by
modulating
activity
antioxidant
enzymes
influencing
signaling
pathways
govern
ROS-induced
inflammation.
Additionally,
microbiota
byproducts,
when
supplemented
through
probiotics,
affect
tumor
microenvironments
enhance
treatment
efficacy
selectively
mediate
destruction
CRC
cells.
This
review
aims
discuss
mechanisms
which
taxonomical
shifts
related
such
as
short-chain
fatty
acids,
secondary
bile
trimethylamine-N-oxide
influence
ROS
concentrations
safeguard
promote
onset
inflammation-mediated
we
focus
on
role
probiotic
ROS-mediated
both
status
inflammation,
Nrf2-Keap1,
NF-κB,
NLRP3
mitigate
carcinogenesis.
Overall,
deeper
understanding
may
aid
delaying
preventing
offer
new
avenues
for
adjunct,
CRC-specific
therapeutic
interventions
immunotherapy.
